A critical role of interleukin-1 in preterm labor

Mathieu Nadeau-Vallée1, Dima Obari2, Christiane Quiniou3

  • 1Departments of Pediatrics, Ophthalmology and Pharmacology, CHU Sainte-Justine Research Center, Montréal H3T 1C5, Canada; Department of Pharmacology, Université de Montréal, Montréal H3C 3J7, Canada.

Insights

Interleukin-1 (IL-1) plays a key role in preterm birth, a major cause of infant mortality. Novel IL-1 therapies and diagnostics show promise for preventing premature labor and improving neonatal outcomes.

Area of Science:

  • Reproductive biology
  • Immunology
  • Neonatal health

Background:

  • Preterm birth (PTB) is a significant global health issue linked to inflammation.
  • Pro-inflammatory cytokines, particularly interleukin-1 (IL-1), are implicated in initiating preterm labor.
  • Existing IL-1 therapies lack efficacy in preclinical models of PTB.

Purpose of the Study:

  • To review IL-1's role in PTB across animal and human studies.
  • To highlight emerging IL-1-targeting therapies and diagnostic tools.
  • To advocate for the commercialization and translation of these advancements.

Main Methods:

  • Systematic review of literature on IL-1 and PTB.
  • Analysis of preclinical and clinical data for IL-1 therapeutics.
  • Evaluation of diagnostic test potential for PTB.

Main Results:

  • IL-1 is a critical mediator in the inflammatory cascade leading to PTB.
  • Novel IL-1 inhibitors and targeted treatments demonstrate potential efficacy.
  • New diagnostic approaches may enable earlier intervention for PTB.

Conclusions:

  • Targeting IL-1 pathways offers a promising therapeutic strategy for PTB.
  • Further development and translation of IL-1-based interventions are crucial.
  • Accelerating commercialization can expedite clinical application and reduce PTB burden.